<SEC-DOCUMENT>0001157523-14-004555.txt : 20141113
<SEC-HEADER>0001157523-14-004555.hdr.sgml : 20141113
<ACCEPTANCE-DATETIME>20141113160553
ACCESSION NUMBER:		0001157523-14-004555
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20141107
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
FILED AS OF DATE:		20141113
DATE AS OF CHANGE:		20141113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Anika Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000898437
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				043145961
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14027
		FILM NUMBER:		141218439

	BUSINESS ADDRESS:	
		STREET 1:		32 WIGGINS AVENUE
		CITY:			BEDFORD
		STATE:			MA
		ZIP:			01730
		BUSINESS PHONE:		(781) 457-9000

	MAIL ADDRESS:	
		STREET 1:		32 WIGGINS AVENUE
		CITY:			BEDFORD
		STATE:			MA
		ZIP:			01730

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANIKA THERAPEUTICS INC
		DATE OF NAME CHANGE:	19970114

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANIKA RESEARCH INC
		DATE OF NAME CHANGE:	19930309
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a50983766.htm
<DESCRIPTION>ANIKA THERAPEUTICS, INC. 8-K
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2014 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-size: 10pt; font-family: Times New Roman">
    <p style="text-align: center">

    </p>
<div style="text-align:left">
    <table cellspacing="0" style="width: 100%; margin-bottom: 10.0px; font-size: 10pt; font-family: Times New Roman">
      <tr>
        <td style="border-bottom: double black 2.25pt">
          &#160;
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <p style="text-align: center">
      <font style="font-size: 11pt; font-family: Times New Roman">UNITED STATES</font><font style="font-size: 11pt; font-family: Times New Roman"><br style="font-size: 11pt; font-family: Times New Roman"></font><font style="font-size: 11pt; font-family: Times New Roman">SECURITIES
      AND EXCHANGE COMMISSION</font><br><font style="font-size: 11pt"><br style="font-size: 11pt"></font><font style="font-size: 11pt">Washington,
      D.C. 20549</font><font style="font-size: 11pt"><br style="font-size: 11pt"></font><font style="font-size: 11pt"><br style="font-size: 11pt"></font><font style="font-size: 11pt; font-family: Times New Roman">FORM
      8-K</font><font style="font-size: 11pt"><br style="font-size: 11pt"></font><font style="font-size: 11pt"><br style="font-size: 11pt"></font><font style="font-size: 11pt">CURRENT
      REPORT</font><font style="font-size: 11pt"><br style="font-size: 11pt"></font><font style="font-size: 11pt">PURSUANT
      TO SECTION 13 OR 15(d)</font><br><font style="font-size: 11pt">OF THE
      SECURITIES EXCHANGE ACT OF 1934</font><font style="font-size: 11pt"><br style="font-size: 11pt"></font><font style="font-size: 11pt"><br style="font-size: 11pt"></font><font style="font-size: 11pt; font-family: Times New Roman">Date
      of Report (Date of earliest event reported): November 7, 2014</font><font style="font-size: 11pt"><br style="font-size: 11pt"></font><font style="font-size: 11pt"><br style="font-size: 11pt"></font><font style="font-size: 11pt">Anika
      Therapeutics, Inc.</font><font style="font-size: 11pt"><br style="font-size: 11pt"></font><font style="font-size: 11pt">(</font><i><font style="font-size: 11pt">Exact
      name of registrant as specified in its charter</font></i><font style="font-size: 11pt">)</font>
    </p>
    <hr style="width: 20%; text-align: center; color: #000000; height: 1.0 pt">


    <p style="text-align: center">

    </p>
    <div style="text-align:center">
    <table cellspacing="0" style="width: 100%; margin-bottom: 10.0px; margin-left:auto;margin-right:auto; font-size: 10pt; font-family: Times New Roman">
      <tr>
        <td style="width: 33%; text-align: center; padding-left: 0.0px" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Massachusetts
          </p>
        </td>
        <td style="padding-right: 0.0px; white-space: nowrap; width: 34%; text-align: center; padding-left: 0.0px" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            000-21326
          </p>
        </td>
        <td style="padding-right: 0.0px; white-space: nowrap; width: 33%; text-align: center; padding-left: 0.0px" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            04-314-5961
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 33%; text-align: center; padding-left: 0.0px" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <i>(State or other jurisdiction of</i><br><i>incorporation or
            organization)</i>
          </p>
        </td>
        <td style="width: 34%; text-align: center; padding-left: 0.0px" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <i>Commission file number</i>
          </p>
        </td>
        <td style="width: 33%; text-align: center; padding-left: 0.0px" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <i>(I.R.S. Employer<br>Identification No.)</i>
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <div style="text-align:center">
    <table cellspacing="0" style="width: 100%; margin-bottom: 10.0px; margin-left:auto;margin-right:auto; font-size: 10pt; font-family: Times New Roman">
      <tr>
        <td style="padding-right: 0.0px; white-space: nowrap; text-align: center; padding-left: 0.0px" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            32 Wiggins Avenue, Bedford, MA 01730
          </p>
        </td>
      </tr>
      <tr>
        <td style="text-align: center; padding-left: 0.0px" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <i>(Address of principal executive offices) (Zip code)</i>
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p style="white-space: nowrap; text-align: center">
      <br>
      <i><font style="font-size: 10pt; font-family: Times New Roman">Registrant&#8217;s
      telephone number, including area code:&#160;&#160;&#160;</font></i><font style="font-size: 10pt; font-family: Times New Roman">781-457-9000</font><br><br><br>
    </p>
    <p style="text-align: center">
      <i><font style="font-size: 10pt; font-family: Times New Roman">(Former
      name or former address, if changed since last report)</font></i><br>
    </p>
    <hr style="width: 20%; text-align: center; color: #000000; height: 1.0 pt">


    <p>

    </p>
    <p>
      <font style="font-size: 10pt; font-family: Times New Roman">Check the
      appropriate box below if the Form 8-K filing is intended to
      simultaneously satisfy the filing obligation of the registrant under any
      of the following provisions:</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Written
      communications pursuant to Rule 425 under the Securities Act (17 CFR
      230.425)</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Soliciting
      material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Pre-commencement
      communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
      240.14d-2(b))</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Pre-commencement
      communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
      240.13e-4(c))</font>
    </p>
<div style="text-align:left">
    <table cellspacing="0" style="width: 100%; margin-bottom: 10.0px; font-size: 10pt; font-family: Times New Roman">
      <tr>
        <td style="border-bottom: double black 2.25pt">
          &#160;
        </td>
      </tr>
    </table>
    </div>
    <p>
      <br>

    </p>
    <div style="margin-left: 0pt; margin-bottom: 10pt; width: 100%; margin-right: 0pt; text-indent: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">

    </p>
    <p style="text-align: center">
      <b>Section 5&#8212;Corporate Governance and Management</b>
    </p>
    <p>

    </p>
    <p style="white-space: nowrap">
      Item 5.02.&#160;&#160;Departure of Certain Officers; Compensatory Arrangements of
      Certain Officers.
    </p>
    <p>

    </p>
    <p>
      Effective November 7, 2014, Anika Therapeutics, Inc. (&#8220;Anika&#8221; or the
      &#8220;Company&#8221;) and John W. Sheets Jr., Ph.D., entered into a separation
      agreement (the &#8220;Agreement&#8221;) regarding his employment with the Company
      through November 7, 2014 (the &#8220;Termination Date&#8221;).&#160;&#160;This Agreement was
      entered into in connection with the previously announced departure of
      Dr. Sheets from his position as the Company&#8217;s Chief Scientific Officer.
      Pursuant to the Agreement, among other items, Dr. Sheets shall receive
      severance pay equal to his final base salary, annualized $340,000, for
      twelve months following the Termination Date on the Company's regular
      payroll schedule, subject to applicable tax withholdings. Under the
      Agreement, Dr. Sheets will not be entitled to any additional payments,
      including bonus payments, from the Company. Dr. Sheets shall be eligible
      to continue to receive medical and dental plan coverage under and
      subject to COBRA, provided that Dr. Sheets is responsible for payment of
      the entire premium and any other amounts necessary to maintain COBRA
      coverage. Dr. Sheets continues to be bound by the terms and conditions
      of the non-disclosure and non-competition agreement executed in
      connection with his employment by the Company. Additionally, in
      consideration of the separation pay and benefits provided by the
      Agreement, Dr. Sheets has released the Company, its directors, and all
      related entities, including, among others, Company officers, employee
      benefit plans, fiduciaries of such plans and other providers of services
      to the Company (together, without limitation, the &#8220;Releasees&#8221;), from all
      known and unknown claims that, as of the date of the Agreement, Dr.
      Sheets had, has ever had, had a claim to have or ever had a claim to
      have against any Releasee.
    </p>
    <p style="text-align: justify">
      <br>
      <br>
      <br>
      <br>
      <br>
      <br>
      <br>
      <br>
      <br>
      <br>
      <br>

    </p>
    <p style="text-align: center">
      [Remainder of page left blank intentionally]
    </p>
    <p>

    </p>
    <p>

    </p>
    <div style="margin-left: 0pt; margin-bottom: 10pt; width: 100%; margin-right: 0pt; text-indent: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman">SIGNATURE</font><br>
    </p>
    <p>
      Pursuant to the requirements of the Securities Exchange Act of 1934, the
      registrant has duly caused this report to be filed on its behalf by the
      undersigned hereunto duly authorized.
    </p>
    <p>

    </p>
    <p>

    </p>
    <div style="text-align:center">
    <table cellspacing="0" style="width: 100%; margin-bottom: 10.0px; margin-left:auto;margin-right:auto; font-size: 10pt; font-family: Times New Roman">
      <tr>
        <td style="width: 50%">

        </td>
        <td style="text-align: left; padding-left: 0.0px" valign="top" colspan="5">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Anika Therapeutics, Inc.
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 50%">

        </td>
        <td style="width: 5%">
          &#160;
        </td>
        <td colspan="3">

        </td>
        <td style="width: 15%; text-align: left; padding-left: 0.0px" valign="top">

        </td>
      </tr>
      <tr>
        <td style="width: 50%">

        </td>
        <td style="width: 5%">

        </td>
        <td style="text-align: left; padding-left: 0.0px" valign="top" colspan="3">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 15%">

        </td>
      </tr>
      <tr>
        <td style="padding-bottom: 2.0px; width: 50%; text-align: left; padding-left: 0.0px" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Dated: November 13, 2014
          </p>
        </td>
        <td style="width: 5%">

        </td>
        <td style="padding-bottom: 2.0px; width: 3%; text-align: left; padding-left: 0.0px" valign="top">
          By:
        </td>
        <td style="width: 4%; text-align: left; border-bottom: solid black 1.0pt; padding-left: 0.0px" valign="top">
          &#160;
        </td>
        <td style="width: 23%; text-align: left; border-bottom: solid black 1.0pt; padding-left: 0.0px" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            /s/ Sylvia Cheung
          </p>
        </td>
        <td style="width: 15%">

        </td>
      </tr>
      <tr>
        <td style="width: 50%">

        </td>
        <td style="width: 5%">

        </td>
        <td style="text-align: left; padding-left: 0.0px" valign="top" colspan="3">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Sylvia Cheung
          </p>
        </td>
        <td style="width: 15%">

        </td>
      </tr>
      <tr>
        <td style="width: 50%">

        </td>
        <td style="width: 5%">

        </td>
        <td style="text-align: left; padding-left: 0.0px" valign="top" colspan="3">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Chief Financial Officer
          </p>
        </td>
        <td style="width: 15%">

        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
  </body>
</html>
<!--<!DOCTYPE html
     PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN"
     "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">-->
<!--<!DOCTYPE html     PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN"     "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">-->
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
